RU2251434C1 - Method for vaccination against rubeola at far north - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: the present innovation deals with vaccinoprophylaxis of rubeola in girls under conditions of Fr North. The method includes immunization with Rudivax vaccine, moreover, the girls who are not 13 during March-July period should be vaccinated next year only, but during the same period, that is since March to July. The method provides protective titers of anti-rubeola antibodies during next year.

EFFECT: higher efficiency of vaccination.

12 ex, 1 tbl

Description

The invention relates to medicine, and can be used for vaccination of rubella among the population of the Far North.

A known method of vaccination against rubella girls aged 13 years [Ministry of Health of the Russian Federation. The new calendar of vaccinations in Russia. Order No. 229. - M .: 06/27/2001].

The known method does not take into account the adaptation of the human immune system to constantly changing climatic parameters in the Far North - “polar night” and “polar day”, short seasons of northern spring, summer and autumn and long cold winters. This determines the low effectiveness of preventive vaccinations and, accordingly, increases the likelihood of rubella. Vaccination according to the known method throughout the year in the Far North provides for significant material and labor costs for the work of medical teams and helicopter transport.

The objective of the invention is to increase efficiency, reduce material and labor costs and simplify the method of vaccination against rubella among girls aged 13-14 years living in the Far North. The task is achieved due to the fact that the female population of the Far North, aged 13-14 years old, is vaccinated only from March to July.

The method is as follows.

In the Far North, girls who have reached the age of 13 who have not been vaccinated or received only one rubella vaccine are invited to the vaccine prevention rooms, where each of them is given the Rudivax vaccine (anti-rubella vaccine) only from March to July. Girls who are under the age of 13 from March to July are vaccinated against rubella in the following year and only from March to July.

Example 1. Andronova M. (age 13 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in January. 1 year after vaccination, anti-rubella antibodies were not detected (Δ OD <0.207) - seronegative.

Example 2. Sotnikova A. (age 14 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in February. One year after vaccination, anti-rubella antibodies were not detected (Δ OD &λτ; 0.207) - seronegative.

Example 3. Shirobokova N. (age 13 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in March. One year after vaccination, anti-rubella antibodies were detected in protective titers (Δ OD = 1.23).

Example 4. Rotmistrova O. (age 14 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in April. One year after vaccination, anti-rubella antibodies were detected in protective titers (Δ OD = 0.932).

Example 5. Kapturova I. (age 13 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in wt. One year after vaccination, anti-rubella antibodies were detected in protective titers (Δ OD = 0.875).

Example 6. Novak A. (age 14 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in June. One year after vaccination, anti-rubella antibodies were detected in protective titers (Δ OD = 0.569).

Example 7. Beloborodova V. (age 13 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in July. One year after vaccination, anti-rubella antibodies were detected in protective titers (Δ OD = 0.408).

Example 8. Khristoforova N. (age 13 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in August. 1 year after vaccination, anti-rubella antibodies were not detected (Δ OD = 0.207) - seronegative.

Example 9. Grishkevich M. (age 14 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in September. 1 year after vaccination, anti-rubella antibodies were not detected (Δ OD <0.207) - seronegative.

Example 10. Zhigalova V. (age 13 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in October. One year after vaccination, anti-rubella antibodies were not detected (Δ OD &λτ; 0.207) - seronegative.

Example 11. Kovaleva I. (age 14 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in November. One year after vaccination, anti-rubella antibodies were not detected (Δ OD &λτ; 0.207) - seronegative.

Example 12. Reasonable S. (age 13 years). Included in the group of people to be vaccinated against rubella. Vaccinated with Rudivax vaccine in December. One year after vaccination, anti-rubella antibodies were not detected (Δ OD &λτ; 0.207) - seronegative.

Note: antibodies to rubella virus were determined by the enzyme immunoassay - at a rate of Δ OD &λτ; 0.207 test sera were considered seronegative (there are no anti-rubella antibodies) - the vaccine is ineffective, with a Δ OD of 0.208-0.404 - anti-rubella antibodies were determined in the test sera in low titers - the vaccine is effective, with a Δ OD of 0.405-1.07 - in the studied sera anti-rubella antibodies were determined in medium titers - the vaccine is effective, with a Δ OD> 1.07 - in the tested sera anti-rubella antibodies were detected in high titers - the vaccine is effective.

In total, in the Far North, 709 girls aged 13-14 are vaccinated with the Rudivax vaccine. All girls were vaccinated in different months (from January to December), while 12 approximately the same groups were formed. The examination was carried out 1 year after vaccination. After vaccination with Rudivax vaccine, from March to July, a smaller amount of seronegative 3.3% -5.0% for rubella virus was recorded than among vaccinated from August to February - 17.2-22.5% (P <0.01) - see table. The most effective rubella vaccination was only shown between March and July.

Using the proposed method has the following advantages: the method of rubella vaccination among girls aged 13-14 years living in the settlements of the Far North is simplified, since the vaccination season is significantly reduced (operation of helicopters and medical teams).

Claims (1)

A method of vaccinating girls against rubella in the Far North, which consists in immunizing with the Rudivax vaccine, characterized in that girls who are under the age of 13 from March to July are vaccinated only next year, in the same period from March to July.